Cite
Patlak-Ki derived from ultra-high sensitivity dynamic total body [18F]FDG PET/CT correlates with the response to induction immuno-chemotherapy in locally advanced non-small cell lung cancer patients.
MLA
Wang, DaQuan, et al. “Patlak-Ki Derived from Ultra-High Sensitivity Dynamic Total Body [18F]FDG PET/CT Correlates with the Response to Induction Immuno-Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer Patients.” European Journal of Nuclear Medicine & Molecular Imaging, vol. 50, no. 11, Sept. 2023, pp. 3400–13. EBSCOhost, https://doi.org/10.1007/s00259-023-06298-x.
APA
Wang, D., Qiu, B., Liu, Q., Xia, L., Liu, S., Zheng, C., Liu, H., Mo, Y., Zhang, X., Hu, Y., Zheng, S., Zhou, Y., Fu, J., Chen, N., Liu, F., Zhou, R., Guo, J., & Fan, W. (2023). Patlak-Ki derived from ultra-high sensitivity dynamic total body [18F]FDG PET/CT correlates with the response to induction immuno-chemotherapy in locally advanced non-small cell lung cancer patients. European Journal of Nuclear Medicine & Molecular Imaging, 50(11), 3400–3413. https://doi.org/10.1007/s00259-023-06298-x
Chicago
Wang, DaQuan, Bo Qiu, QianWen Liu, LiangPing Xia, SongRan Liu, ChaoJie Zheng, Hui Liu, et al. 2023. “Patlak-Ki Derived from Ultra-High Sensitivity Dynamic Total Body [18F]FDG PET/CT Correlates with the Response to Induction Immuno-Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer Patients.” European Journal of Nuclear Medicine & Molecular Imaging 50 (11): 3400–3413. doi:10.1007/s00259-023-06298-x.